Veraxa Biotech AG (NasdaqGM: VRXA)
Health Care · Biotechnology · DE
$1.87
-6.03% today · -82.1% 1Y
Veraxa Biotech AG (NasdaqGM: VRXA) operates in the Biotechnology industry within the Health Care sector. The company is valued at $47.16M and employs 8 people.
Over the last twelve months the share price has lost 82.1%, trading between 1.70 and 27.36.
VRXA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $47.16M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- —
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $27.36
- 52-week low
- $1.70
- Avg volume (3M)
- —
- Shares outstanding
- 25.22M
- Employees
- 8
- Next earnings
- —
About Veraxa Biotech AG
Veraxa Biotech Holding AG is a clinical-stage biopharmaceutical company, formed via a merger with Voyager Acquisition Corp., focusing on developing next-generation cancer therapies such as antibody-drug conjugates (ADCs) and bispecific T-cell engagers. [64, 65]
- ISIN
- CH1476899161
- Founded
- 2021
- Listed since
- Jun 9, 2026
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $264.52 | -0.17% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $443.84 | +1.03% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $63.06B | €864.20 | -4.19% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $138.89 | -4.26% |
Figures last refreshed Aug 18, 2026.